This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

David DiLillo, PhD
Senior Staff Scientist at Regeneron Pharmaceuticals

Profile

David DiLillo is a Staff Scientist in the Immuno-Oncology department at Regeneron Pharmaceuticals in New York, where he leads a team investigating novel T cell-retargeting technologies. His team is responsible for IND-enabling as well as mechanistic in vitro and in vivo studies using Regeneron’s unique bispecific antibody platform to treat both liquid and solid tumors. His team also actively investigates chimeric antigen receptor (CAR) T cell biology in similar model systems. Dr. DiLillo holds a Ph.D. in Immunology from Duke University, where he studied non-classical B cell effector functions, and he completed his postdoctoral studies in Fc-receptor biology at the Rockefeller University.